<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25597595</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2015</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.</ArticleTitle><Pagination><StartPage>7878</StartPage><MedlinePgn>7878</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7878</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep07878</ELocationID><Abstract><AbstractText>Hand-foot-and-mouth disease (HFMD) has been recognized as an important global public health issue, which is predominantly caused by enterovirus 71 (EV-A71) and coxsackievirus A16 (CVA16). There is no available vaccine against HFMD. An ideal HFMD vaccine should be bivalent against both EV-A71 and CVA16. Here, a novel strategy to produce bivalent HFMD vaccine based on chimeric EV-A71 virus-like particles (ChiEV-A71 VLPs) was proposed and illustrated. The neutralizing epitope SP70 within the capsid protein VP1 of EV-A71 was replaced with that of CVA16 in ChiEV-A71 VLPs. Structural modeling revealed that the replaced CVA16-SP70 epitope is well exposed on the surface of ChiEV-A71 VLPs. These VLPs produced in Saccharomyces cerevisiae exhibited similarity in both protein composition and morphology as naive EV-A71 VLPs. Immunization with ChiEV-A71 VLPs in mice elicited robust Th1/Th2 dependent immune responses against EV-A71 and CVA16. Furthermore, passive immunization with anti-ChiEV-A71 VLPs sera conferred full protection against lethal challenge of both EV-A71 and CVA16 infection in neonatal mice. These results suggested that this chimeric vaccine, ChiEV-A71 might have the potential to be further developed as a bivalent HFMD vaccine in the near future. Such chimeric enterovirus VLPs provide an alternative platform for bivalent HFMD vaccine development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hao-Yang</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Jian-Feng</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yong-Qiang</ForeName><Initials>YQ</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shun-Ya</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Feng</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hui-Qin</ForeName><Initials>HQ</Initials><AffiliationInfo><Affiliation>1] Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China [2] Guangzhou No. 8 People's Hospital, Guangzhou Medical College, Guangzhou 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue-Xiang</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>E-De</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Cheng-Feng</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25597595</ArticleId><ArticleId IdType="pmc">PMC4297979</ArticleId><ArticleId IdType="doi">10.1038/srep07878</ArticleId><ArticleId IdType="pii">srep07878</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Secrest A. M. &amp; Shah K. N. Picture of the month. Hand-foot-and-mouth disease. JAMA Pediatr 167, 387&#x2013;388 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23545603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L. X. et al. Epidemiology of hand, foot, and mouth disease and genotype characterization of Enterovirus 71 in Jiangsu, China. J Clin Virol 49, 100&#x2013;104 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20719557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K. et al. Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol 43, 6171&#x2013;6175 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317214</ArticleId><ArticleId IdType="pubmed">16333123</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrero L. J. et al. Molecular epidemiology of enterovirus 71 in peninsular Malaysia, 1997&#x2013;2000. Arch Virol 148, 1369&#x2013;1385 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12827466</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y. et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 14, E1076&#x2013;E1081 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu P. V. et al. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis 13, 1733&#x2013;1741 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375788</ArticleId><ArticleId IdType="pubmed">18217559</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip C. C., Lau S. K., Woo P. C. &amp; Yuen K. Y. Human enterovirus 71 epidemics: what's next? Emerg Health Threats J 6, 19780 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Center for Disease Control and Prevention. National Health Data&amp; Statistics.
http://www.chinacdc.cn/en/informationresource/.</Citation></Reference><Reference><Citation>Han J. F. et al. Phenotypic and genomic characterization of human coxsackievirus A16 strains with distinct virulence in mice. Virus Res 179, 212&#x2013;219 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24211607</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q. et al. Coxsackievirus A16: Epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother 10, 360&#x2013;367 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P. N. &amp; Shih S. R. Update on enterovirus 71 infection. Curr Opin Virol 5C, 98&#x2013;104 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24727707</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P. C. Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol 2, 199&#x2013;205 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22482716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y. J. et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccin Immunother 10 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4896521</ArticleId><ArticleId IdType="pubmed">24633366</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J. X., Mao Q. Y., Liang Z. L., Ji H. &amp; Zhu F. C. Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials. Expert Rev Vaccines 13, 609&#x2013;618 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24621093</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang E. et al. Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vaccin Immunother 10 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4896597</ArticleId><ArticleId IdType="pubmed">24583556</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi An W. et al. The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems. Hum Vaccin Immunother 10 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4130287</ArticleId><ArticleId IdType="pubmed">24401488</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J. et al. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol 95, 1083&#x2013;1093 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983757</ArticleId><ArticleId IdType="pubmed">24496826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H. et al. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol 97, 10445&#x2013;10452 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24085395</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip C. C. et al. Emergence of enterovirus 71 "double-recombinant" strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Arch Virol 155, 1413&#x2013;1424 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087135</ArticleId><ArticleId IdType="pubmed">20549263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K. et al. Circulating coxsackievirus A16 identified as recombinant type A human enterovirus, China. Emerg Infect Dis 17, 1537&#x2013;1540 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381541</ArticleId><ArticleId IdType="pubmed">21801645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K. et al. Human enterovirus 71 uncoating captured at atomic resolution. J Virol 88, 3114&#x2013;3126 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957924</ArticleId><ArticleId IdType="pubmed">24352461</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Perera R., Cardosa J., Kuhn R. J. &amp; Rossmann M. G. Crystal structure of human enterovirus 71. Science 336, 1274 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. Y., Han J. F., Qin C. F. &amp; Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31, 3281&#x2013;3287 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y. L. et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 30, 1305&#x2013;1312 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q. W. et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 30, 6642&#x2013;6648 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J. et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 28, 3516&#x2013;3521 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Jiang S. &amp; Wang Y. Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice. Biochem Biophys Res Commun 430, 387&#x2013;393 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23159634</ArticleId></ArticleIdList></Reference><Reference><Citation>Premanand B. et al. Induction of protective immune responses against EV71 in mice by baculovirus encoding a novel expression cassette for capsid protein VP1. Antiviral Res 95, 311&#x2013;315 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22691220</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D. G., Alonso S., Chow V. T. &amp; Poh C. L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9, 1299&#x2013;1306 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D. G. et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Research 125, 61&#x2013;68 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C. C. et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29, 4362&#x2013;4372 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X. et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 88, 72&#x2013;81 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y. X. et al. Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice. Virol J 11, 79 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4030048</ArticleId><ArticleId IdType="pubmed">24885030</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X. et al. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS One 7, e41381 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3407240</ArticleId><ArticleId IdType="pubmed">22848478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho S. Y. et al. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates. Infect Immun 76, 111&#x2013;119 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2223651</ArticleId><ArticleId IdType="pubmed">17954727</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19, 424&#x2013;429 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann M. G., He Y. &amp; Kuhn R. J. Picornavirus-receptor interactions. Trends Microbiol 10, 324&#x2013;331 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12110211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J. et al. Picornavirus uncoating intermediate captured in atomic detail. Nat Commun 4, 1929 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709478</ArticleId><ArticleId IdType="pubmed">23728514</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Huang X., Liu Q. &amp; Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine 31, 2130&#x2013;2136 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong M. et al. Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development. J Virol 88, 6444&#x2013;6452 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4093858</ArticleId><ArticleId IdType="pubmed">24672036</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y. et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 31, 2215&#x2013;2221 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23499596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K. et al. Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach. Vaccine 30, 7105&#x2013;7110 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23022400</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y. et al. Cross-reactivity of anti-EV71 IgM and neutralizing antibody in series sera of patients infected with Enterovirus 71 and Coxsackievirus A 16. J Immunoassay Immunochem 32, 233&#x2013;243 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21574094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei R. et al. A dominant EV71-specific CD4+ T cell epitope is highly conserved among human enteroviruses. PLoS One 7, e51957 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3522610</ArticleId><ArticleId IdType="pubmed">23251663</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan Y. F. &amp; AbuBaker S. Recombinant human enterovirus 71 in hand, foot and mouth disease patients. Emerg Infect Dis 10, 1468&#x2013;1470 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3320397</ArticleId><ArticleId IdType="pubmed">15496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukashev A. N. Role of recombination in evolution of enteroviruses. Rev Med Virol 15, 157&#x2013;167 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15578739</ArticleId></ArticleIdList></Reference><Reference><Citation>Messer W. B. et al. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A 111, 1939&#x2013;1944 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918811</ArticleId><ArticleId IdType="pubmed">24385585</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu H. et al. Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions. J Virol 86, 7964&#x2013;7975 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421688</ArticleId><ArticleId IdType="pubmed">22623776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward R. L., Clark H. F. &amp; Offit P. A. Influence of potential protective mechanisms on the development of live rotavirus vaccines. J Infect Dis 202 Suppl S72&#x2013;79 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20684721</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R. Y. et al. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS One 8, e64024 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659118</ArticleId><ArticleId IdType="pubmed">23700449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen I. C., Wang S. M., Yu C. K. &amp; Liu C. C. Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med Microbiol Immunol 202, 259&#x2013;265 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23408291</ArticleId></ArticleIdList></Reference><Reference><Citation>Flipse J., Wilschut J. &amp; Smit J. M. Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic 14, 25&#x2013;35 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22998156</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorlani A. &amp; Forthal D. N. Antibody-dependent enhancement and the risk of HIV infection. Curr HIV Res 11, 421&#x2013;426 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24191936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Yedidia T. &amp; Arnon R. Epitope-based vaccine against influenza. Expert Rev Vaccines 6, 939&#x2013;948 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18034655</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F. et al. Enterovirus 71 viral capsid protein linear epitopes: identification and characterization. Virol J 9, 26 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292509</ArticleId><ArticleId IdType="pubmed">22264266</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Ku Z., Liu Q., Leng Q. &amp; Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 32, 2406&#x2013;2412 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24657161</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J. F. et al. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J 8, 106 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>